Go to page
 

Bibliographic Metadata

Title
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
AuthorValenta, Rudolf ; Campana, Raffaela ; Focke-Tejkl, Margit ; Niederberger, Verena
Published in
Journal of Allergy and Clinical Immunology, New York, 2016, Vol. 137, Issue 2, page 351-357
PublishedNew York : Elsevier, 2016
LanguageEnglish
Document typeJournal Article
Keywords (EN)allergy / allergen / allergen-specific immunotherapy / allergy vaccine / preventive allergy vaccine / bet v 1 / grass-pollen allergy / virus-like particles / t-cell reactivity / combination vaccines / blocking antibodies / immunoglobulin-e / cat allergy / hay-fever / intralymphatic immunotherapy
Project-/ReportnumberF 4605-B28
ISSN0091-6749
URNurn:nbn:at:at-ubmuw:3-1931 Persistent Identifier (URN)
DOI10.1016/j.jaci.2015.12.1299 
Restriction-Information
 The work is publicly available
Files
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future [0.87 mb]
Links
Reference
Classification
Abstract (English)

In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom allergens. Allergy vaccines in clinical trials based on recombinant allergens, recombinant allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.

Stats
The PDF-Document has been downloaded 3 times.
License
CC-BY-NC-ND-License (4.0)Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License